| Similar Articles |
|---|
 |
The Motley Fool
February 27, 2007
Billy Fisher |
OSI Eyeing Growth in '07 Despite recent mixed results, the pharmaceutical has higher hopes for the year. Investors, take note.   |
The Motley Fool
May 3, 2007
Billy Fisher |
Optimism for OSI With Tarceva sales growing across the board and the potential for new uses on the horizon, coupled with a shrewd divestiture of an unprofitable product, the general outlook for OSI appears to be quite favorable. Investors, take note. |
The Motley Fool
May 5, 2005
Charly Travers |
OSI's Cancer Blockbuster Tarceva will turn OSI Pharmaceuticals into a leading biotech. |
The Motley Fool
August 1, 2007
Billy Fisher |
Overseas Growth Sparks OSI's Earnings OSI Pharmaceuticals continues to prosper, and it has Tarceva to thank. But what happens when Tarceva becomes obsolete around 2009? Investors, take note. |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
The Motley Fool
April 26, 2004
Alyce Lomax |
Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug. |
The Motley Fool
August 22, 2005
Rich Duprey |
Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies. |
The Motley Fool
January 26, 2009
Brian Orelli |
Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues. |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
InternetNews
October 16, 2007
Sean Michael Kerner |
Microsoft: The Open Source Company Microsoft joins the open source community today with the blessing of the Open Source Initiative. |
InternetNews
August 17, 2007
Sean Michael Kerner |
Stop Whining: Let's All Be (C)PALS New open source license draws converts to Open Source Initiative approval. |
The Motley Fool
January 5, 2005
Charly Travers |
AstraZeneca's Lead Evaporates Pulling an application for Iressa from the EU makes the drug a has-been. |
The Motley Fool
May 28, 2009
Brian Orelli |
Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us. |
InternetNews
August 9, 2007
Sean Michael Kerner |
Does Open Source Licensing Matter? According to a panel at LinuxWorld, licensing may not matter at all. |
The Motley Fool
January 10, 2007 |
OSI's Final Course: Fool by Numbers OSI Restaurant Partners released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
November 19, 2004
Charly Travers |
A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer. |
The Motley Fool
December 20, 2004
Charly Travers |
More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped. |
The Motley Fool
July 10, 2008
Brian Lawler |
Lilly Targets a Tiny Prize As drugmakers go, this acquisition's a value meal. |
InternetNews
March 31, 2005
Michael Singer |
Intel Wants Off Open Source Listing Open source software advocates say that's A.O.K. with them. |
InternetNews
May 31, 2005
Jim Wagner |
OSI Group to Slow License Influx? Officials will begin addressing the open source license rush in June, but it wants the community involved. |
The Motley Fool
January 22, 2010
Brian Orelli |
Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line. |
The Motley Fool
August 17, 2007
Brian Lawler |
The Perfect Pharma Acquisition The pharmaceutical industry has been busy consolidating in the past year. With so much buying and selling going on, here is speculation on what would constitute the perfect pharma acquisition. |
Registered Rep.
February 1, 2005
Bob Hirschfeld |
Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street. |
The Motley Fool
July 6, 2009
Brian Orelli |
Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer. |
The Motley Fool
December 30, 2009
Brian Orelli |
Pfizer Pflubs -- You Expected Otherwise? Bad news, but rather expected. |
The Motley Fool
December 3, 2004
W.D. Crotty |
One Hot Biotech Stock Biomira reports favorable Phase II test results, sending the stock up 146%. |
InternetNews
February 1, 2005
Michael Singer |
OSI President Eric Raymond Steps Down The open source licensing group to expand the scope of its activities, with new board members. |
The Motley Fool
May 25, 2005
Tom Taulli |
Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note. |
InternetNews
August 23, 2005
Jim Wagner |
OSI's Open Flap The goals of the Open Source initiative's license proliferation committee were thrown into question when the creator of the organization's manifesto, Bruce Perens, was recently denied entrance. |
The Motley Fool
November 21, 2008
Brian Orelli |
The Comeback of the Century? AstraZeneca is trying to revive Iressa. |
The Motley Fool
November 9, 2006 |
Barr Pharmaceuticals Barrels Ahead: Fool by Numbers The pharmaceutical released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
InternetNews
April 4, 2005
Jim Wagner |
OSI Tackles License 'Explosion' The Open Source Initiative will hold a meeting Wednesday to crack down on the proliferation of open source licenses. |
The Motley Fool
August 28, 2008
Rich Smith |
OSI Sandbagged Its strong sales growth could soon be mired in quicksand, and rightfully so. |
InternetNews
July 27, 2007
Sean Michael Kerner |
OpenMFG Takes on QuickBooks With PostBooks xTuple takes aim at off-the-shelf ERP wannabes with new PostBooks solution. |
The Motley Fool
October 20, 2006
Motley Fool Contributors |
Semi-Gilded Lilly: Fool by Numbers The pharmaceutical released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 7, 2008
Rich Smith |
I Spy OSI OSI, the airport security checkpoint equipment manufacturer, beats analyst estimates for the fifth consecutive quarter. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead. |
InternetNews
February 10, 2010 |
What Does Open Source Value Most? Open source is defined by licenses, but that's not the end of the discussion, according to the president of the Open Source Initiative. |
The Motley Fool
November 10, 2006 |
Sales Down at King Pharmaceuticals: Fool by Numbers The pharmaceutical released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 23, 2004
David Nierengarten |
Genentech's Star Power How much higher can Genentech go? |
The Motley Fool
January 19, 2007
Stephen Albainy-Jenei |
The Best Drug Stock for 2007: Genentech Now that growth is starting to level off for Genentech's four main oncology drugs, many analysts have lowered their ratings and cooled on Genentech's future. But the company is more than just a list of drugs. |
InternetNews
January 3, 2011 |
Novell-Attachmate Deal Under Fire in Europe Novell's fate seemed to be sealed when it announced its agreement to sell to privately held Attachmate for $2.2 billion, but a condition of that transaction could hold up the sale. |
The Motley Fool
October 21, 2005
Seth Jayson |
SanDisk's Slam Dunk: Fool by Numbers The leading flash-memory maker released third-quarter 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
August 16, 2006
Anders Bylund |
The Fighting Photronics: Fool by Numbers The company released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
October 20, 2006
Ryan Fuhrmann |
3M's in Shape: Fool by Numbers The diversified conglomerate released fiscal third-quarter 2006 earnings. Here are the quick details for the quarter. |
The Motley Fool
October 26, 2006
Anders Bylund |
Taiwan Semi Fully Loaded: Fool by Numbers The broad-line semiconductor foundry released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
June 6, 2006
Nathan Parmelee |
OSI Has a Pirate On Board Pirate Capital urges OSI Restaurant Partners to speed up its shareholder value initiatives or prepare for a proxy battle. A little outside pressure can help to focus management on moving more quickly and also highlight the need to deliver on promises. |
InternetNews
July 25, 2007
Sean Michael Kerner |
GPLv3 Scores Big Win With SugarCRM SugarCRM has changed directions, announcing today that it will move to the GPL version 3 for the upcoming release of Sugar Community Edition 5.0, which is expected in September. |
The Motley Fool
October 27, 2006 |
GlaxoSmithKline's Great Q3: Fool by Numbers The pharmaceutical released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
January 12, 2007
Matthew Crews |
OSI: A Farewell Toast OSI Restaurant partners reports its last quarterly earnings before going private. |
